TrialLancet (London, England)2016

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Nicholas D James et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.